eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Response-adapted therapy of stage III-IV Hodgkin lymphoma using early interim FDG-PET imaging

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
    Fludeoxyglucose F 18
  3. Intervention
  4. Intervention
  5. Intervention
    Doxorubicin hydrochloride
  6. Intervention
  7. Intervention
  8. Intervention
    Procarbazine hydrochloride
  9. Intervention
    Vinblastine sulfate
  10. Intervention
    Vincristine sulfate
  11. Additional Topic(s)
    Antineoplastic combined chemotherapy protocols
  12. Resource Description
    RATIONALE: G-CSF may help lessen the side effects in patients receiving chemotherapy. Imaging procedures, such as fludeoxyglucose F 18-PET/CT imaging, may help doctors predict how patients will respond to treatment. PURPOSE: This phase II trial is studying fludeoxyglucose F 18-PET/CT imaging to see how well it works in assessing response to combination chemotherapy and allow doctors to plan better additional further treatment in treating patients with stage III or stage IV Hodgkin lymphoma.
  13. Contact
    Berenberg, Jeffrey
  14. PI
    Berenberg, Jeffrey
  15. Topic
    Hodgkin's lymphoma
  16. Study Population
    Males and females from ages 18 to 60 years are eligible.
  17. Funded by
  18. Phase
    Phase 2 clinical trial
  19. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016